Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation
Menée à l'aide de données 2001-2017 du registre danois des cancers portant sur 4 015 témoins et 803 patients atteints d'un lymphome agressif (durée médiane de suivi : 7,8 ans ; 67 % d'hommes), cette étude analyse le risque de second cancer primitif lié au traitement par chimiothérapie à haute dose et autogreffe de cellules souches hématopoïétiques
Autologous haematopoietic stem-cell transplantation (HSCT) involves collecting the stem cells of a patient, administering high-dose chemotherapy or radiation to eradicate the underlying haematological disease, and then reinfusing the collected stem cells to restore bone marrow. This procedure allows for the administration of high-dose chemotherapy while minimising damage to the bone marrow and immune system. Autologous HSCT has shown success in achieving complete remission and even long-term survival for some lymphoma subtypes. However, the benefits of autologous HSCT come with inherent risks, one of which is the potential development of secondary primary malignancies (SPMs).
The Lancet Haematology , commentaire, 2022